In EV-301, EV monotherapy was associated with a significant improvement in both progression-free survival (PFS) and overall survival (OS) in comparison to single-agent chemotherapy in patients with mUC who had previously been treated with PBC and PD-1/PD-L1 inhibitors, which ultimate led to US Food and Drug Administration approval of EV for this patient population [16]. The gene discussed is CD274; the disease is primary biliary cholangitis.